BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.
-
Upload
red-espanola-de-investigacion-en-salud-del-hombre -
Category
Health & Medicine
-
view
93 -
download
0
description
Transcript of BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.
![Page 1: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/1.jpg)
GUÍAS PARA HBP:¿DE DONDE VENIMOS
Y DONDE VAMOS?
Eduard García [email protected]
@drgarciacruzwww.reisho.com
Eduard García CruzUrología y Salud del Hombre
Servicio de UrologíaBarnaclínic
Hospital Clínic de [email protected]
@drgarciacruzwww.reisho.com
Conflict of interest: he recibido fondos para investigación de BAYER, Lilly, Pfizer, Olympus, Auxilium y Janssen, he formado parte de comités asesores para Bayer, Lilly, Janssen, Gebro, Italpharmaco and Menarini y soy ponente para Lilly, GSK y Bayer.
![Page 2: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/2.jpg)
“Tempus irreparabile fugit” Virgilio
![Page 3: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/3.jpg)
“Tempus irreparabile fugit” Virgilio
![Page 4: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/4.jpg)
¿CÓMO HAN EVOLUCIONADO LAS GUIDELINES EN HBP RESPECTO…
1. AL DIAGNÓSTICO?
2. AL TRATAMIENTO MÉDICO?
3. AL TRATAMIENTO QUIRÚRGICO?
![Page 5: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/5.jpg)
¿CÓMO HAN EVOLUCIONADO LAS GUIDELINES EN HBP RESPECTO…
1. AL DIAGNÓSTICO?
2. AL TRATAMIENTO MÉDICO?
3. AL TRATAMIENTO QUIRÚRGICO?
![Page 6: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/6.jpg)
![Page 7: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/7.jpg)
![Page 8: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/8.jpg)
![Page 9: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/9.jpg)
![Page 10: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/10.jpg)
RIESGO DE PROGRESIÓN
Próstata >30ccPSA >1,5
Qmax <10ml/segRPM >40ml
![Page 11: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/11.jpg)
¿CÓMO HAN EVOLUCIONADO LAS GUIDELINES EN HBP RESPECTO…
1. AL DIAGNÓSTICO?
2. AL TRATAMIENTO MÉDICO?
3. AL TRATAMIENTO QUIRÚRGICO?
![Page 12: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/12.jpg)
¿CÓMO HAN EVOLUCIONADO LAS GUIDELINES EN HBP RESPECTO…
1. AL DIAGNÓSTICO?
2. AL TRATAMIENTO MÉDICO?
3. AL TRATAMIENTO QUIRÚRGICO?
![Page 13: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/13.jpg)
![Page 14: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/14.jpg)
FITOTERAPIA ALFA-BLOQUEANTE
S
5-ARI COMBO WW
= 5-ARI Beneficios sostenidos
Finasteride> 40cc
No IPSS<7
![Page 15: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/15.jpg)
![Page 16: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/16.jpg)
FITOTERAPIA ALFA-BLOQUEANTE
S
5-ARI COMBO WW
= 5-ARI Beneficios sostenidos
Finasteride> 40cc
No IPSS <7
DesconocidoBeneficios sostenidos.
Finasteride (>40cc) y
dutasteride, alteran Hª
natural HBP.No alt PCa
Si IPSS <15
![Page 17: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/17.jpg)
![Page 18: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/18.jpg)
FITOTERAPIA ALFA-BLOQUEANTE
S
5-ARI COMBO WW
= 5-ARI Beneficios sostenidos
Finasteride> 40cc
No IPSS <7
DesconocidoBeneficios sostenidos.
Finasteride (>40cc) y
dutasteride, alteran Hª
natural HBP.No alt PCa
Si IPSS <15
No se puede concluir
IPSS >7 Finasteride
(>40cc) y dutasteride alteran Hª
natural.
Si IPSS <7
* *
![Page 19: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/19.jpg)
Hombres >50 añosPróstata >30cc
PSA >1,5IPSS >12
>4.800 hombres
![Page 20: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/20.jpg)
![Page 21: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/21.jpg)
![Page 22: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/22.jpg)
RIESGO DE PROGRESIÓN
Próstata >30ccPSA >1,5
Qmax <10ml/segRPM >40ml
![Page 23: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/23.jpg)
¿CÓMO HAN EVOLUCIONADO LAS GUIDELINES EN HBP RESPECTO…
1. AL DIAGNÓSTICO?
2. AL TRATAMIENTO MÉDICO?
3. AL TRATAMIENTO QUIRÚRGICO?
![Page 24: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/24.jpg)
¿CÓMO HAN EVOLUCIONADO LAS GUIDELINES EN HBP RESPECTO…
1. AL DIAGNÓSTICO?
2. AL TRATAMIENTO MÉDICO?
3. AL TRATAMIENTO QUIRÚRGICO?
![Page 25: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/25.jpg)
![Page 26: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/26.jpg)
![Page 27: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/27.jpg)
![Page 28: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/28.jpg)
![Page 29: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/29.jpg)
Estratificar por riesgo de progresión.
Analizar síntomas (nocturia, inversión de diuresis, OAB, esfera sexual).
Combinación en hombres con riesgo de progresión.
Desde el punto de vista quirúrgico, múltiples opciones. HoLEP comparable a prostatectomía .
![Page 30: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/30.jpg)
“Tempus irreparabile fugit” Virgilio
![Page 31: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/31.jpg)
GUÍAS PARA HBP:¿DE DONDE VENIMOS
Y DONDE VAMOS?
Eduard García [email protected]
@drgarciacruzwww.reisho.com
Eduard García CruzUrología y Salud del Hombre
Servicio de UrologíaBarnaclínic
Hospital Clínic de [email protected]
@drgarciacruzwww.reisho.com
Conflict of interest: he recibido fondos para investigación de BAYER, Lilly, Pfizer, Olympus, Auxilium y Janssen, he formado parte de comités asesores para Bayer, Lilly, Janssen, Gebro, Italpharmaco and Menarini y soy ponente para Lilly, GSK y Bayer.
![Page 32: BPH Guidelines evolution from 2001 to 2012. Where do we come from and where are we going.](https://reader033.fdocuments.in/reader033/viewer/2022060117/558530b0d8b42a30308b4d9c/html5/thumbnails/32.jpg)